JHIU
NKTR icon

Janus Henderson Investors US’s Nektar Therapeutics NKTR Stock Holding History

Janus Henderson Investors US’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$40.1M Sell
113,982
-5,241
-4% -$1.18M 0.03% 488
2016
Q4 		$21.9M Sell
119,223
-3,879
-3% -$789K 0.02% 597
2016
Q3 		$31.7M Sell
123,102
-15,018
-11% -$3.87M 0.03% 517
2016
Q2 		$29.5M Sell
138,120
-7,133
-5% -$1.59M 0.03% 509
2016
Q1 		$30M Sell
145,253
-12,695
-8% -$2.44M 0.03% 508
2015
Q4 		$39.9M Buy
157,948
+4,845
+3% +$996K 0.03% 492
2015
Q3 		$25.2M Buy
153,103
+32,323
+27% +$5.72M 0.02% 558
2015
Q2 		$22.7M Buy
120,780
+21,545
+22% +$3.71M 0.02% 587
2015
Q1 		$16.4M Buy
99,235
+15,042
+18% +$3.09M 0.01% 649
2014
Q4 		$19.6M Buy
84,193
+5,456
+7% +$1.17M 0.02% 608
2014
Q3 		$14.3M Buy
78,737
+10,540
+15% +$2.02M 0.01% 638
2014
Q2 		$13.1M Sell
68,197
-5,865
-8% -$1.04M 0.01% 626
2014
Q1 		$13.5M Buy
74,062
+11,504
+18% +$2.28M 0.01% 616
2013
Q4 		$10.7M Sell
62,558
-6,251
-9% -$1.01M 0.01% 657
2013
Q3 		$10.8M Sell
68,809
-20,403
-23% -$3.77M 0.01% 638
2013
Q2 		$15.5M Buy
+89,212
New +$13.7M 0.02% 547

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Investors US's NKTR Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Nektar Therapeutics (NKTR) stake by 4.4% in Q1 2017, selling an estimated $1.18M and leaving 113,982 shares worth $40.1M. The position accounts for 0.03% of the portfolio, ranked #488.

Janus Henderson Investors US first reported a position in NKTR in Q2 2013 and has held it in 16 quarters since. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

  • Janus Henderson Investors US held 113,982 shares of Nektar Therapeutics worth $40.1M as of Q1 2017.
  • Janus Henderson Investors US sold 5,241 Nektar Therapeutics shares in Q1 2017, an estimated $1.18M.
  • Nektar Therapeutics made up 0.03% of Janus Henderson Investors US's portfolio in Q1 2017, its #488 holding.
  • Janus Henderson Investors US first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 16 quarters since.
  • 201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.